Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS: In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. RESULTS: Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1-positive and PD-L1-negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. CONCLUSIONS: Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies examining the clinical activity of single agent anti-PD-1/PD-L1 therapies in the neoadjuvant setting have reported MPR rates between 19% and 45% in patients with resectable NSCLC14–16.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, studies of neoadjuvant immunotherapy in patients with resectable NSCLC reported responses irrespective of PD-L114,21,”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cited by
Items 201–300 of 1,000
Hofman, P. M., Badoual, C., Henderson, F., Berland, L., Hamila, M., Long-Mira, É., Lassalle, S., Roussel, H., Hofman, V., Tartour, É., et al. (2019) · Cancers · doi:10.3390/cancers11030283 · Cited by 127
“Interestingly, a recent clinical trial has supported the role for neoadjuvant immunotherapy in surgically resectable NSCLC, suggesting that the neoadjuvant regimen may lead to early induction of an adaptive anti-tumor immunity, which could be responsible for preventing distant metastases [6].”
BackgroundTiming of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
Liu, J., O’Donnell, J. S., Yan, J., Madore, J., Allen, S., Smyth, M. J., & Teng, M. W. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581530 · Cited by 113
“In contrast, two cycles of neoadjuvant nivolumab monotherapy in patients with resectable early NSCLC (stage I, II, or IIIA), reportedmajor pathological response in 9 of 20 resected tumors (45%)(NCT02259621).(18) All 20 patients who received nivolumab had a successful resection of their tumors 4 weeks after commencemen…”
BackgroundMasarwy, R., Kampel, L., Horowitz, G., Gutfeld, O., & Muhanna, N. (2021) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2021.2191 · Cited by 118
Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
Petrella, F., Rizzo, S., Attili, I., Passaro, A., Zilli, T., Martucci, F., Bonomo, L. D., Grande, F. D., Casiraghi, M., de Marinis, F., et al. (2023) · Current Oncology · doi:10.3390/curroncol30030239 · Cited by 135
“The results of these trials showed that the ICI treatment had no adverse effects on surgical outcomes, with previously unreported response rates ranging from 14–45% and a pathological complete response (pCR) up to 16% with single agent anti-PD-1/PD-L1 [70,71].”
BackgroundResultZhao, Z.-R., Yang, C., Chen, S., Yu, H., Lin, Y., Lin, Y., Qi, H., Jin, J., Lian, S., Wang, Y., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1996000 · Cited by 114
Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy
Brown, Z. J., Greten, T. F., & Heinrich, B. (2019) · Hepatology · doi:10.1002/hep.30633 · Cited by 114
“Neoadjuvant pembrolizumab proved to be safe and efficacious in patients with non-small cell lung cancer.(57) In patients with stage 3 melanoma, perioperative ipilimumab and nivolumab expanded more tumor-resident T cells than adjuvant therapy alone.”
BackgroundZhong, Z., Vong, C. T., Chen, F., Tan, H., Zhang, C., Wang, N., Cui, L., Wang, Y., & Feng, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21876 · Cited by 118
“It was shown to induce a pathological response to 45% of resected lung cancer cells as predicted by theTMB with few side effects, regardless of PD‐L1 expression.(46) TILs are white blood cells and traffic towards tumor beds.”
BackgroundAdjuvant and Neoadjuvant Immunotherapy in Non–small Cell Lung Cancer
Broderick, S. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.001 · Cited by 113
Self-citationImmunotherapy in Colorectal Cancer: Current and Future Strategies
Ooki, A., Shinozaki, E., & Yamaguchi, K. (2021) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2020-064 · Cited by 118
“In early-stage NSCLC, a pilot study (NCT02259621) of neoadjuvant therapy with nivolumab showed a major pathological response of 45% with few AEs, and no incidences of delayed surgery were determined[88].”
BackgroundYue, D., Liu, W., Chen, C., Zhang, T., Ma, Y., Cui, L., Gu, Y., Bei, T., Zhao, X., Zhang, B., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-106 · Cited by 124
“The discordance between radiologic and pathological response underpins the need to develop effective biomarkers that can accurately predict therapeutic efficacy (10,11).”
BackgroundMethodChen, X., Xu, X. M., Wang, D., Liu, J., Sun, J. P., Lu, M., Wang, R., Hui, B., Li, X., Zhou, C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005830 · Cited by 123
“Higher TMB was shown to be associated with better MPR rates in CheckMate 159 27 but not in LCMC3.”
Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy.
Ju, X., Zhang, H., Zhou, Z., & Wang, Q. (2020) · PubMed · Cited by 133
Zhang, Y., Fu, F., Hu, H., Wang, S., Li, Y., Hu, H., & Chen, H. (2020) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2020.02.131 · Cited by 121
Jiang, T., Shi, J., Dong, Z., Hou, L., Zhao, C., Li, X., Mao, B., Zhu, W., Guo, X., Zhang, H., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0762-1 · Cited by 121
“A pilot study found that neoadjuvant nivolumab resulted in a major pathological response of 45% [18].”
BackgroundClinical approaches to overcome PARP inhibitor resistance
Zou, Y., Zhang, H., Chen, P., Tang, J., Yang, S., Nicot, C., Guan, Z., Li, X., & Tang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02355-1 · Cited by 132
“This heightened TMB is a proxy for neoantigen load, a critical factor in ICI efficacy [139].”
Self-citationMolecular imaging biomarkers for immune checkpoint inhibitor therapy
van de Donk, P. P., de Ruijter, L. K., Hooge, M. N. L., Brouwers, A. H., van der Wekken, A. J., Oosting, S. F., Fehrmann, R. S. N., de Groot, D. J. A., & de Vries, E. G. E. (2020) · Theranostics · doi:10.7150/thno.38339 · Cited by 110
“This data suggests that an increase in T cell numbers already occurs within a few weeks after the start of treatment (80-86).”
BackgroundMethodSun, Y., Luo, J., Chen, Y., Cui, J., Lei, Y., Cui, Y., Jiang, N., Jiang, W., Chen, L., Chen, Y., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106198 · Cited by 111
Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy
van Pul, K. M., Fransen, M. F., van de Ven, R., & de Gruijl, T. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643291 · Cited by 107
Emerging evidence and treatment paradigm of non-small cell lung cancer
Liu, S. M., Zheng, M.-M., Pan, Y., Liu, S. M., Li, Y., & Wu, Y.-L. L. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01436-2 · Cited by 119
“Treatment with ICIs improved the pCR rate to 10–30% and MPR rate to 30–50% [35, 36, 61].”
BackgroundMartínez-Usatorre, A., Kadioglu, E., Boivin, G., Cianciaruso, C., Guichard, A., Torchia, B., Zangger, N., Nassiri, S., Keklikoglou, I., Schmittnaegel, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1616 · Cited by 118
Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
Zhang, L., Hao, B., Geng, Z., & Geng, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730666 · Cited by 111
Deng, H., Zhao, Y., Cai, X., Chen, H., Cheng, B., Zhong, R., Li, F., Xiong, S., Li, J., Liu, J., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103582 · Cited by 109
He, W., Leng, X., Mao, T., Luo, X., Zhou, L., Yan, J., Peng, L., Fang, Q., Liu, G., Wei, X., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab011 · Cited by 102
Allaf, M. E., Kim, S.-E., Master, V. A., McDermott, D. F., Harshman, L. C., Cole, S., Drake, C. G., Signoretti, S., Akgül, M., Baniak, N., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00211-0 · Cited by 119
Guo, X., Nie, H., Zhang, W., Li, J., Ge, J., Xie, B., Hu, W., Zhu, Y., Zhong, N., Zhang, X., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.001 · Cited by 100
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
Santarpía, M., Aguilar, A., CHAIB-OUKADOUR, I., Cardona, A. F., Fancelli, S., Laguía, F., Bracht, J. W. P., Cao, P., Molina‐Vila, M. Á., Karachaliou, N., et al. (2020) · Cancers · doi:10.3390/cancers12061475 · Cited by 116
“MPR was observed in 57% of patients and pathologic complete response in 33% of patients [81].”
BackgroundEscape from nonsense-mediated decay associates with anti-tumor immunogenicity
Litchfield, K., Reading, J. L., Lim, E. L., Xu, H., Liu, P., Bakir, M. A., Wong, Y. N. S., Rowan, A., Funt, S. A., Merghoub, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17526-5 · Cited by 112
“Tumor mutation burden (TMB) is associated with response to immunotherapy across multiple tumor types, and therapeutic modalities, including checkpoint inhibitors (CPIs) and cellular based therapy (1-8) (9, 10).”
BackgroundSelf-citationNeoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
Long, G. V., Menzies, A. M., & Scolyer, R. A. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02575 · Cited by 109
Jia, X., Xu, H., Geng, L., Jiao, M., Wang, W., Jiang, L., & Guo, H. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.001 · Cited by 110
Self-citationEpigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 111
Montagne, F., Guisier, F., Vénissac, N., & Baste, J. (2021) · Cancers · doi:10.3390/cancers13153711 · Cited by 111
“Concerning neo-adjuvant immunotherapy, in the first trial [158], major pathological response was reported in 45% patients from the immunotherapy group vs 10% without immunotherapy.”
Sepesi, B., Zhou, N., William, W. N., Lin, H. Y., Leung, C. H., Weissferdt, A., Mitchell, K. G., Pataer, A., Walsh, G. L., Rice, D. C., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.01.019 · Cited by 108
Neoadjuvant treatment of colorectal cancer: comprehensive review
Smith, H. G., Nilsson, P. J., Shogan, B. D., Harji, D. P., Gambacorta, M. A., Romano, Â., Brandl, A., & Qvortrup, C. (2024) · BJS Open · doi:10.1093/bjsopen/zrae038 · Cited by 114
“Encouraged by studies in other solid cancers, which demonstrated increased activity of ICIs in the neoadjuvant rather than adjuvant or metastatic settings 133–135 , several recent trials have investigated the potential of ICIs as a neoadjuvant treatment in patients with colon or rectal cancers.”
BackgroundProvencio, M., Nadal, E., Insa, A., Campelo, R. G., Casal, J., Dómine, M., Massutí, B., Majem, M., Rodríguez‐Abreu, D., Martínez‐Martí, A., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00498-4 · Cited by 99
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
Althammer, S., Tan, T. H., Spitzmüller, A., Rognoni, L., Wiestler, T., Herz, T., Widmaier, M., Rebelatto, M. C., Kaplon, H., Damotte, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0589-x · Cited by 99
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 110
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma
Knochelmann, H. M., Horton, J. D., Liu, S., Armeson, K. E., Kaczmar, J. M., Wyatt, M. M., Richardson, M. S., Lomeli, S. H., Xiong, Y., Graboyes, E. M., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100426 · Cited by 104
“N2c 2 (16) Clinical stage (%) II 3 (25)”
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 114
“described the results of a clinical trial of neoadjuvant anti-PD-1 mAbs (nivolumab) for resectable early-stage lung cancer (stage I, II, or IIIA) in 21 patients, with 45% of 20 patients observed to have a major pathologic response at the primary tumor site [269].”
BackgroundCui, X., Liu, S., He, S., Xu, J., & Sun, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02287-w · Cited by 129
“Immunotherapy has become the first-line treatment for NSCLC, and neoadjuvant immunotherapy before surgical resection in patients with resectable NSCLC has resulted in longer event-free survival and a higher rate of pathological complete response [10, 11].”
Shibata, H., Saito, S., & Uppaluri, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.727433 · Cited by 110
Berland, L., Heeke, S., Humbert, O., Macocco, A., Long-Mira, E., Lassalle, S., Lespinet-Fabre, V., Lalvée, S., Bordone, O., Cohen, C., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.102 · Cited by 95
Shen, D., Chen, Q., Wu, J., Li, J., Tao, K., & Jiang, Y. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-599 · Cited by 101
“In the Checkmate-159 trial, the volume of tumor increased preoperatively evaluated by CT in two patients, and there was no or the negligible amounts of residual tumor in surgical specimens (11).”
BackgroundResultInfluentialKidane, B., Bott, M. J., Spicer, J. D., Backhus, L. M., Chaft, J. E., Chudgar, N. P., Colson, Y. L., D’Amico, T. A., David, E. A., Lee, J. S.-J., et al. (2023) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2023.04.039 · Cited by 122
Self-citationSato, Y., Fu, Y., Liu, H., Lee, M. Y., & Shaw, M. H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08974-3 · Cited by 109
Yin, J., Yuan, J., Li, Y., Fang, Y., Wang, R., Jiao, H., Tang, H., Zhang, S., Lin, S., Feng, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02469-3 · Cited by 108
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
Liang, W., Cai, K., Chen, C., Chen, H., Chen, Q., Fu, J., Hu, J., Jiang, T., Jiao, W., Li, S., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-2020-63 · Cited by 105
“5–8%, and the completion rate of planned surgery was 78–100%, which are all similar to those of NCT and NRT (26-28).”
BackgroundMethodInfluentialUpdated Prognostic Factors in Localized NSCLC
Garinet, S., Wang, P., Mansuet‐Lupo, A., Fournel, L., Wislez, M., & Blons, H. (2022) · Cancers · doi:10.3390/cancers14061400 · Cited by 108
She, Y., He, B., Wang, F., Zhong, Y., Wang, T., Liu, Z., Yang, M., Yu, B., Deng, J., Sun, X., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104364 · Cited by 91
Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses
Kidman, J., Principe, N., Watson, M. W., Lassmann, T., Holt, R. A., Nowak, A. K., Lesterhuis, W. J., Lake, R., & Chee, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587014 · Cited by 102
“A pre-treatment tumor TCRb repertoire with reduced diversity correlates with clinical response to anti-PD-1 therapy in some melanoma, and lung cancer patient cohorts (13, 17, 40), but not others (69, 70).”
BackgroundSchüler, M., Cuppens, K., Plönes, T., Wiesweg, M., Pont, B. D., Hegedűs, B., Köster, J., Mairinger, F. D., Darwiche, K., Paschen, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02965-0 · Cited by 100
“Achieving R0 resections in 95% of patients compares favorably with other studies of ICI-based neoadjuvant treatment in NSCLC with operation rates mostly around 80% 9,11–18 .”
Hsiehchen, D., Watters, M. K., Lü, R., Xie, Y., & Gerber, D. E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.11519 · Cited by 94
Chuntova, P., Chow, F. E., Watchmaker, P. B., Galvez, M., Heimberger, A. B., Newell, E. W., Diaz, A. A., DePinho, R. A., Li, M. O., Wherry, E. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa277 · Cited by 96
de Rodas, M. L., Villalba-Esparza, M., Sanmamed, M. F., Chen, L., Rimm, D. L., & Schalper, K. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00984-x · Cited by 109
“In a study of neoadjuvant nivolumab monotherapy for NSCLC, higher T cell clonality was found in the resected tumour in patients with a major pathological response 204 .”
Friedman, J., Moore, E. C., Zolkind, P., Robbins, Y., Clavijo, P. E., Sun, L., Greene, S., Morisada, M. V., Mydlarz, W. K., Schmitt, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2209 · Cited by 88
“Indeed, early reports on the use of single-agent neoadjuvant PD-1 immune checkpoint blockade in patients with melanoma and lung cancer have demonstrated promising results with high rates of clinical-topathologic downstaging and even complete regression of tumor in subsets of patients (49, 50).”
BackgroundPalma, D. A., Nguyen, T. K., Louie, A. V., Malthaner, R. A., Fortin, D., Rodrigues, G., Yaremko, B., Laba, J. M., Kwan, K. F., Gaede, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6993 · Cited by 95
Tao, X., Li, N., Wu, N., He, J., Ying, J., Gao, S., Wang, S., Wang, J., Wang, Z., Ling, Y., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04711-3 · Cited by 95
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 94
“, published the first pilot study investigating two preoperative doses of nivolumab, a PD-1 inhibitor, in patients with stage I, II, or IIIA NSCLC in the CheckMate-159 trial (50).”
BackgroundHe, M., He, Q., Cai, X., Liu, J., Deng, H., Li, F., Zhong, R., Lu, Y. H., Peng, H., Wu, X., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005539 · Cited by 104
Li, J., Xiao, Z., Wang, D., Jia, L., Nie, S., Zeng, X., & Hu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01844-5 · Cited by 105
“Clinical studies have shown that blocking PD-1 or CTLA-4/PD-1 at the same time has a synergistic effect with immunotherapy for multiple solid tumors [378, 379].”
BackgroundLévesque, S., Le Naour, J., Pietrocola, F., Paillet, J., Kremer, M., Castoldi, F., Baracco, E. E., Wang, Y., Vacchelli, E., Stoll, G., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1657375 · Cited by 86
Cellular determinants and therapeutic implications of inflammation in pancreatic cancer
Stone, M. L., & Beatty, G. L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.012 · Cited by 90
Dykema, A. G., Zhang, J., Cheung, L. S., Connor, S. C., Zhang, B., Zeng, Z., Cherry, C., Li, T., Caushi, J. X., Nishimoto, M., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg1487 · Cited by 94
Self-citationTumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer
Cascone, T., Fradette, J. J., Pradhan, M., & Gibbons, D. L. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037895 · Cited by 100
Wang, S., Zhang, J., He, Z., Wu, K., & Liu, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32327 · Cited by 92
Self-citationMyeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 86
Bae, J., Liu, L., Moore, C., Hsu, E. J., Zhang, A., Ren, Z., Sun, Z., Wang, X., Zhu, J., Shen, J., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01024-5 · Cited by 91
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Li, H., Zandberg, D. P., Kulkarni, A., Chiosea, S. I., Santos, P. M., Isett, B. R., Joy, M., Sica, G., Contrera, K. J., Tatsuoka, C. M., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.026 · Cited by 102
Patel, J. J., Levy, D. A., Nguyen, S. A., Knochelmann, H. M., & Day, T. A. (2019) · Head & Neck · doi:10.1002/hed.26036 · Cited by 88
“Seiwert (2016) Phase Ib 2b 60 49 (82) 63 (20-83) Pembrolizumab PD1 USA and Israel”
BackgroundInfluentialHecht, M., Gostian, A., Eckstein, M., Rutzner, S., von der Grün, J., Illmer, T., Hautmann, M., Klautke, G., Laban, S. A., Brunner, T. B., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001378 · Cited by 85
Dykema, A. G., Zhang, B., Woldemeskel, B. A., Garliss, C. C., Cheung, L. S., Choudhury, D. M., Zhang, J., Aparicio, L., Bom, S., Rashid, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146922 · Cited by 92
Self-citationTumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
Linette, G. P., & Carreno, B. M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00523-x · Cited by 89
He, B., Johansson, A., Backhouse, J., Li, J., Lee, G., Hamzah, J., & Ganß, R. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.013 · Cited by 85
Salehi‐Rad, R., Li, R., Paul, M. K., Dubinett, S. M., & Liu, B. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.003 · Cited by 94
Ludford, K., Cohen, R., Svrcek, M., Foo, W. C., Colle, R., Parc, Y., Thomas, J. V., Morris, V. K., Kopetz, S., Chang, G. J., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djaa052 · Cited by 80
Eichhorn, F., Klotz, L. V., Kriegsmann, M., Bischoff, H. G., Schneider, M. A., Muley, T., Kriegsmann, K., Haberkorn, U., Heußel, C. P., Savai, R., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.01.018 · Cited by 88
Huang, X., Liu, Q., Zhong, G., Peng, Y., Liu, Y., Liang, L., Hong, H., Feng, W., Yang, S., Zhang, Y., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02510-2 · Cited by 87
Self-citationSeban, R., Moya‐Plana, A., Antonios, L., Yeh, R., Marabelle, A., Deutsch, É., Schwartz, L. H., Gómez, R. G. H., Saenger, Y. M., Robert, C., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04757-3 · Cited by 88
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
Goldmacher, G., Khilnani, A. D., Andtbacka, R. H. I., Luke, J. J., Hodi, F. S., Marabelle, A., Harrington, K. J., Perrone, A., Tse, A. N., Madoff, D. C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02985 · Cited by 85
“Because radiographic assessment might not correlate with tissue response and loss of FDG uptake in injected lesions may represent necrosis, biopsy may provide additional information in case of doubt.(26,27)”
BackgroundXing, W., Zhao, L., Zheng, Y., Liu, B., Liu, X., Li, T., Zhang, Y., Ma, B., Yang, Y., Shang, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772450 · Cited by 89
“When the anti-PD-1 antibody was applied alone, the T cells with antitumor activity in peripheral blood reached the peak at 1 or 2 weeks after the first dose of anti-PD-1 antibody and then decreased gradually (28).”
BackgroundSelf-citationChung, V., Kos, F. J., Hardwick, N., Yuan, Y., Chao, J., Li, D., Waisman, J., Li, M., Zurcher, K., Frankel, P., et al. (2019) · Clinical and Translational Oncology · doi:10.1007/s12094-018-1932-2 · Cited by 78
“However, there is a growing interest in conducting similar trials in patients with earlier stage of disease in the neoadjuvant setting [33].”
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma
Flippot, R., Escudier, B. J., & Albiges, L. K. (2018) · Drugs · doi:10.1007/s40265-018-0970-y · Cited by 81
“The interest of this approach has been validated in resectable non-small-cell lung cancer, in a Phase 2 study where 45% of patients had major pathologic response after two courses of neoadjuvant nivolumab [43].”
BackgroundReview of Immune Therapies Targeting Ovarian Cancer
Fan, C., Reader, J. C., & Roque, D. M. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0584-3 · Cited by 82
Ohmura, H., Yamaguchi, T., Hanamura, F., Ito, M., Makiyama, A., Uchino, K., Shimokawa, H., Tamura, S., Esaki, T., Mitsugi, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0810-1 · Cited by 81
“In non-squamous cell lung cancer patients, the T cell repertoire of peripheral blood before and after nivolumab administration and of TILs in the resected tumour tissue was evaluated, and neoantigen specific T cell clones appeared and increased transiently after PD-1 therapy.(29) Peripheral blood T cells exhibiting me…”
BackgroundCombination immunotherapy strategies for glioblastoma
Chan, H. Y., Choi, J. H., Jackson, C., & Lim, M. K. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03481-0 · Cited by 79
“Results from neoadjuvant ICB in melanoma and non-small cell lung cancer have also seen promising responses; neoadjuvant anti-PD-1 in these cancer tissues demonstrated an increase in both T cell clonality and diversity upon treatment, thereby indicating viable T cell activation from antigen presenting cells [44, 45].”
BackgroundResultSelf-citationNeoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma
Gorin, M. A., Patel, H. D., Rowe, S. P., Hahn, N. M., Hammers, H. J., Pons, A., Trock, B. J., Pierorazio, P. M., Nirschl, T. R., Salles, D. C., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.04.002 · Cited by 79
Self-citationZhou, Z., Ding, Z., Yuan, J., Shen, S., Jian, H., Tan, Q., Yang, Y., Chen, Z., Luo, Q., Cheng, X., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01283-7 · Cited by 82
Zhang, C., Yin, K., Liu, S. M., Yan, L., Su, J., Wu, Y.-L. L. C., Zhang, X., Zhong, W., & Yang, X.-N. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002312 · Cited by 88
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 83
Redman, J. M., Friedman, J., Robbins, Y., Sievers, C., Yang, X., Lassoued, W., Sinkoe, A., Papanicolau-Sengos, A., Lee, C.-C., Marte, J. L., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci161400 · Cited by 74
“Although challenging because of very low clonotype frequencies, detection of tumor antigen specificity in peripheral blood may yield a more comprehensive list of patient-specific neoepitopes if TILs cultured after ICB are unavailable for study (6, 32).”
BackgroundPulmonary toxicity of immune checkpoint immunotherapy
Ghanbar, M., & Suresh, K. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170503 · Cited by 88
Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer
Boumber, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.120 · Cited by 79
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue
Litchfield, K., Stanislaw, S., Spain, L., Gallegos, L. L., Rowan, A., Schnidrig, D., Rosenbaum, H., Harlé, A., Au, L., Hill, S. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107550 · Cited by 86
Kim, J. W., Márquez, C. P., Kostyrko, K., Koehne, A. L., Marini, K. D., Simpson, D. R., Lee, A. G., Leung, S. G., Sayles, L. C., Shrager, J. B., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0612-2 · Cited by 84
Yang, S., Cao, B., Zhou, G., Zhu, L., Wang, L., Zhang, L., Kwok, H. F., Zhang, Z., & Zhao, Q. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01089 · Cited by 76
Self-citationVascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy
Liu, Z., Zhao, Q., Zheng, Z., Liu, S., Meng, L., Dong, L., & Jiang, X. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111607 · Cited by 83
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Rosner, S., Reuss, J. E., ZAHURAK, M. L., Zhang, J., Zeng, Z., Taube, J. M., Anagnostou, V., Smith, K. N., Riemer, J., Illei, P. B., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2994 · Cited by 75
“Study endpoints and biomarkers Primary endpoints of this study were safety and feasibility both having been previously reported (6).”
BackgroundResultInfluentialSelf-citationLiu, S.-L., Li, X. N., Yang, J.-H., Wen, D., Guo, S., Liu, L., Li, Y., Luo, M.-J., Xie, S., Liang, Y.-J., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00504-7 · Cited by 85
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma
Pinato, D. J., Fessas, P., Sapisochin, G., & Marron, T. U. (2021) · Hepatology · doi:10.1002/hep.31697 · Cited by 74
“(27) Interestingly, while radiographic responses are often lagging and pathologic response rates are frequently manyfold higher than would be suggested by preoperative imaging assessments,(19) immune monitoring from neoadjuvant studies suggests that the peak benefit of this therapy may be seen within the first week.”
BackgroundTumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer
Inamura, K., Takazawa, Y., Inoue, Y., Yokouchi, Y., Kobayashi, M., Saiura, A., Shibutani, T., & Ishikawa, Y. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7070172 · Cited by 73
“Emerging immunotherapies, including anti-PD-1 (PDCD1)/PD-L1 (CD274) antibodies, have been used effectively to treat several types of cancers, including non-small-cell lung cancer (NSCLC) and malignant melanoma [11,12]; however, these therapies lack efficacy in treating pancreatic cancers, partly due to their abundant…”
BackgroundGalli, G., Triulzi, T., Proto, C., Signorelli, D., Imbimbo, M., Poggi, M. M., Fucà, G., Ganzinelli, M., Vitali, M., Palmieri, D., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.008 · Cited by 76
Metadata
- Authors
- Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K. A., Verde, F., Guo, H., Zhang, J., Caushi, J. X., Chan, H. Y., Sidhom, J.-W., Scharpf, R. B., White, J., Gabrielson, E., Wang, H., Rosner, G. L., Rusch, V., Wolchok, J. D., Merghoub, T., Taube, J. M., Velculescu, V. E., Topalian, S. L., Brahmer, J. R., & Pardoll, D. M.
- Affiliations
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Forde, Patrick M.
- Chaft, Jamie E.
- Smith, Kellie N.
- Anagnostou, Valsamo
- Cottrell, Tricia R.
- Hellmann, Matthew D.
- Zahurak, Marianna
- Yang, Stephen C.
- Jones, David R.
- Broderick, Stephen
- Velez, Moises J.
- Rekhtman, Natasha
- Naidoo, Jarushka
- Marrone, Kristen A.
- Verde, Franco
- Guo, Haidan
- Zhang, Jiajia
- Caushi, Justina X.
- Sidhom, John-William
- Scharpf, Robert B.
- White, James
- Wang, Hao
- Rosner, Gary L.
- Rusch, Valerie
- Wolchok, Jedd D.
- Merghoub, Taha
- Taube, Janis M.
- Velculescu, Victor E.
- Topalian, Suzanne L.
- Brahmer, Julie R.
- Pardoll, Drew M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-24
- Volume
- 378
- Issue
- 21
- Pages
- 1976-1986
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6223617
- OpenAlex
- W2798160602
- Cited by
- 2,099
- References
- 33
- Citations by year
- 2026: 123 · 2025: 181 · 2024: 241 · 2023: 304 · 2022: 304 · 2021: 342 · 2020: 279 · 2019: 214 · 2018: 110
- FWCI
- 89.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- International Association for the Study of Lung Cancer
- LUNGevity Foundation
- MacMillan Foundation
- Lung Cancer Foundation of America
- National Cancer Institute (CA006973, CA121113, CA180950, CA193145, P30 CA006973, P30 CA008748, R01 CA142779, T32 CA193145)
- ECOG-ACRIN
- Commonwealth Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Bristol-Myers Squibb
- Bloomberg–Kimmel Institute for Cancer Immunotherapy
- Stand Up To Cancer (SU2C-AACR-DT1012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- neoadjuvant immunotherapy, anti-PD-1 therapy, nivolumab, resectable non-small cell lung cancer, early-stage lung cancer, pathological response, PD-L1 expression, tumor mutational burden, predictive biomarkers, treatment safety and feasibility
- MeSH terms
- Nivolumab, Adenocarcinoma, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Biopsy, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pilot Projects, Neoadjuvant Therapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.